发明名称 |
Re-directed immunotherapy |
摘要 |
The invention provides an agent for preventing or treating a condition characterized by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells. |
申请公布号 |
US9358282(B2) |
申请公布日期 |
2016.06.07 |
申请号 |
US201514660137 |
申请日期 |
2015.03.17 |
申请人 |
The University of Birmingham |
发明人 |
Cobbold Mark;Millar David |
分类号 |
C07K14/005;C07K16/28;A61K45/06;A61K38/20;A61K39/395;A61K39/245;A61K47/48;A61K39/12;C07K16/32;A61K39/08;A61K39/145;A61K39/235;C12N7/00;A61K39/00 |
主分类号 |
C07K14/005 |
代理机构 |
McNeill Baur PLLC |
代理人 |
McNeill Baur PLLC |
主权项 |
1. An agent for retargeting T cells to cancer cells, the agent comprising:
(i) a targeting moiety that is capable of targeting to the cancer cells, wherein the targeting moiety is Rituximab or Cetuximab; (ii) a T cell epitope capable of eliciting a T cell response in a subject, wherein the T cell epitope is NLVPMVATV (SEQ ID NO: 21), and (iii) a peptide linker comprising a peptide cleavage site cleavable by a tumor associated protease and wherein the linker can be selectively cleaved by the tumor associated protease to release the T cell epitope in the vicinity of, and outside of, the cancer cell. |
地址 |
Birmingham GB |